News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CyDex Pharmaceuticals Announces CAPTISOL(R) Technology Used in Recently Approved Cosolvent-Free Formulation of Amiodarone IV


1/5/2009 9:41:18 AM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals’ NEXTERONE®, which recently received new drug application (NDA) approval from the U.S. Food and Drug Administration (FDA), is based on the patent-protected CyDex CAPTISOL® technology platform. NEXTERONE is the first CyDex proprietary product to achieve the milestone of NDA approval.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES